The way we plan and conduct clinical investigations for medical devices must be adjusted to 21st century standards
Jón Ingi Bergsteinsson
At a seminar in Tel Aviv for medical device manufacturers this April, Jón Ingi Bergsteinsson, MEDEI's Vice President for Global Business Development, laid out the reasons why.
Global revenues of the medical technology industry are expected to jump from $425 billion in 2018 to $522 billion in 2022, according to statistics portal Statista.
From helping humans to live longer to repairing the body and understanding the brain, medtech has and will continue to have a massive impact on the well-being of global communities.
So, with medtech being such a critical part of today's ageing world, the question has to be asked ... are clinical trials and evaluation methods ready for our highly-digitised era?
Clinical evaluation is one of the hottest topics in the medical device industry. With the recent updates in the European Union's Medical Device Regulation (MDR), which become mandatory in May 2018, more focus is being placed on clinical evidence.
With MDR, clinical evaluation of medical devices now becomes a permanent process and one that must be covered by plans and reports.
Manufacturers will have to present their clinical data if requested by Notified Bodies and this might require some organisations to have direct access to data on device benefits and safety.
This can prove to be troublesome for an industry that's governed by basic analogue processes and legacy tools.
To comply with MDR and have access to the European market, the process behind clinical evaluation of medical devices has to change and adhere to more modern standards.
Otherwise, manufacturers will risk increased R&D costs and further loss of knowledge. If the process behind generating clinical evidence is not optimised, manufacturers will also risk prolonged time-to-market, which impacts both budgets and revenues.
At a recent seminar for professionals in the medical device industry staged in Tel Aviv, the subject of clinical trial data topped the agenda.
Staged by MEDEI, MedicSense and the Embassy of Denmark in Israel, more than 30 delegates from Israel's burgeoning device manufacturing industry had the opportunity to talk with experts about the implications of MDR and the impact on clinical operations.
At the seminar, clinical evidence was defined as the process by which you collect and document scientific aspects of clinical safety and outcomes when applying a method or a solution to a certain care pathway.
Generating clinical evidence for medical devices requires both the collection of data and scientific documentation. The process requires teamwork between various specialised groups, including those in clinical, engineering, quality control and regulatory know-how. All of which are often packed into clinical studies that involve sponsors, healthcare professionals and patients.
The process of generating clinical evidence is often modelled as a "waterfall" activity around clinical investigations in typical phases.
For most medical device manufacturers, this process is often very slow, troublesome and inefficient. Delays are very common and exceeding budgets has become the norm.
This is because of the fact that it is governed by analogue tools and outdated methods. Paper is often the main method of data collection and Excel the most dominant "database." But Excel is not a database.
Additionally, there is a lack of overview coupled with issues of missing data and loss of knowledge. This is because of the poor data structure and inconsistent storage of evidence.
As a result, collaboration becomes inefficient and a lot of time (and money) is spent on status updates, and other time-consuming tasks such as transcription.
However, the new MDR calling for access to data does not make the process easier to complete.
From MEDEI's experience, partners who request improvement in their method of data collection eventually end up with an enhancement in the overall process as well.
The use of the study data management tool SMART-TRIAL can often influence transformation in the overall process, not just a part of it and inspire change.
There are three governing actions that device manufacturers should take to improve clinical evidence.
Digitise clinical data collection: Because the age of paper has passed, and the requirements for an overview improved, security has increased.
Not only is paper bad for the environment but time-consuming and costly. Time and money spent on transcription, missing data and faulty collection could instead be aimed at R&D and product development.
A computer screen can display numbers and reports on status faster than any analogue report. It can become extremely time-consuming to look through paper-based reports or files.
Data security is becoming increasingly important, especially regarding the new EU General Data Protection Regulation (GDPR). Access to sensitive data must be done in coherence with standards of the 21st century, which don't limit access to it.
Stowing paper-based data away at remote locations with strong access control does not help, if the data is not easily attainable.
Start at the end: First, focus on the end-results of the study and how graphs should look and be presented. Work retrospectively from there before writing the clinical study protocol.
Secondly, don't leap from graphs to protocol writing. Testing the data collection methods and forms can increase the efficiency in writing the protocols.
This results in less time spent on writing the protocol. By first creating the forms and designing the study flow, less time is spent on defining it as the whole set up can be visualised.
Additionally, early test and set-up design result in fewer amendments throughout the study course.
Lastly, the study endpoints become clearer. Your data collection will represent endpoints that mirror your study specific requirements. Not results from the adjusted protocols from a previous study, or from a protocol template.
We've seen too many cases of a waterfall process in which older protocols end up being mirrored for an upcoming study. This results in unclear results and often useless data.
Design better forms: There are no benefits from electrifying paper. Paper and electronic systems, or electronic case report forms (eCRF) and electronic patient reported outcomes (ePRO), look and function differently.
By modelling paper or analogous forms, we neglect the advantages of the digital solution.
We need to collect more quantifiable data. Quantifiable data is important when applying statistical methods to collected data, but people often end up collecting a lot of free text and other misleading data that doesn't help.